Last update :
18/04/2024
Anticancer drug   Cisplatin  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Abiplatin Republic of South Africa
Accocit Mexico
Briplatin Japan
Cisplatex Brazil
Cisplatin Australia, Austria, Belgium, Canada, Saudi Arabia
Cisplatina Brazil
Cisplatine Belgium, France
Cisplatyl France, Greece, Saudi Arabia, Turkey
Citoplatino Argentina, Italy
Citoplax Brazil
Corsis Mexico
Insel Brazil
Neoplatin Spain
Pamifect India
Placis Spain, Turkey
Platamine Greece, Italy, Morocco, Tunisia
Platanovag Argentina
Platiblastin Austria
Platidiam Hungary, Poland
Platinex Germany, Great Britain, Italy
Platinol Austria, Belgium, Denmark, Finland, Greece, Luxembourg, Mexico, Netherlands, Sweden, Switzerland, United States of America
Platistil Spain
Platistine Belgium, Brazil, Luxembourg
Platosin Belgium, Egypt, Greece, Japan, Netherlands, Romania, Turkey, Venezuela
Pronto Platamine Italy
Zuridry Mexico

Factors which affect stability   Injection   Factors which affect stability : Cisplatin        
References
Storage Light Induces Degradation 410
Solvent Glucose 5% Induces Degradation 3578
Solvent Parenteral nutrition (binary mixture) Induces Degradation 301
Solvent NaHCO3 Induces Degradation 3578
Temperature Increase Induces Degradation 1729
Temperature 4°C[ > 0,5 mg / ml] Induces Precipitation 164
Temperature 4°C[ > 0,6 mg / ml] Induces Precipitation 742
PH Increase Induces Degradation 410
[Cl-] < 0,3% Induces Degradation 409

  Mentions Légales